Drug Trial Radar · NCT07038343
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Jun 4, 2025
Primary completion
Jun 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- Avenzo Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- DualityBio Inc.
- First posted
- Jun 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.
Conditions
- Solid Tumor Cancer
- Locally Advanced
- Metastatic Solid Tumors
- Lung Cancers
- Epithelial Tumor
- Biliary Tract Cancer (BTC)
- Urothelial Cancer
- Nasopharyngeal Cancers
Interventions
AVZO-1418Drug
Specific dose in protocol specified schedule
Combination Agent 1Drug
Per label based on combination agent used
Combination Agent 2Drug
Per label based on combination agent used
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1)Time frame: Approximately 2 years
- Determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) (Phase 1)Time frame: Approximately 16 months
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1)Time frame: From baseline until end of study treatment or study completion (approximately 2 years)
- Objective Response Rate (ORR) (Phase 2)Time frame: From baseline through disease progression or study completion (approximately 2 years)
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
Avenzo Therapeutics Recruiting Site
Gilbert, Arizona · Recruiting
Avenzo Therapeutics Recruiting Site
Los Angeles, California · Recruiting
Avenzo Therapeutics Recruiting Site
Los Angeles, California · Recruiting
Avenzo Therapeutics Recruiting Site
Denver, Colorado · Recruiting
Avenzo Therapeutics Recruiting Site
New Haven, Connecticut · Recruiting
Avenzo Therapeutics Recruiting Site
Washington D.C., District of Columbia · Recruiting
Avenzo Therapeutics Recruiting Site
Orlando, Florida · Recruiting
Avenzo Therapeutics Recruiting Site
Sarasota, Florida · Recruiting
Avenzo Therapeutics Recruiting Site
Tampa, Florida · Recruiting
Avenzo Therapeutics Recruiting Site
Atlanta, Georgia · Recruiting
Avenzo Therapeutics Recruiting Site
Boston, Massachusetts · Recruiting
Avenzo Therapeutics Recruiting Site
New York, New York · Recruiting
Avenzo Therapeutics Recruiting Site
Philadelphia, Pennsylvania · Recruiting
Avenzo Therapeutics Recruiting Site
Dallas, Texas · Recruiting
Avenzo Therapeutics Recruiting Site
Houston, Texas · Recruiting
Avenzo Therapeutics Recruiting Site
San Antonio, Texas · Recruiting
Avenzo Therapeutics Recruiting Site
West Valley City, Utah · Recruiting
Avenzo Therapeutics Recruiting Site
Fairfax, Virginia · Recruiting
Avenzo Therapeutics Recruiting Site
Seattle, Washington · Recruiting
DualityBio Recruiting Site
Beijing, Beijing Municipality, China · Recruiting
DualityBio Recruiting Site
Chongqing, Chongqing Municipality, China · Recruiting
DualityBio Recruiting Site
Harbin, Heilongjiang, China · Recruiting
DualityBio Recruiting Site
Zhengzhou, Henan, China · Recruiting
DualityBio Recruiting Site
Changsha, Hunan, China · Recruiting
DualityBio Recruiting Site
Nanchang, Jiangxi, China · Recruiting
DualityBio Recruiting Site
Shenyang, Liaoning, China · Recruiting
DualityBio Recruiting Site
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.